{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:14Z","timestamp":1790716814504,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T00:00:00Z","timestamp":1603670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.543046","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:40:41Z","timestamp":1603687241000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Use of Patient Preference Information in Benefit\u2013Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts and Initiatives"],"prefix":"10.3389","volume":"7","author":[{"given":"Lylia","family":"Chachoua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Dussart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Aball\u00e9a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mondher","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40258-013-0023-3","article-title":"Patient preferences versus physicians' judgement: does it make a difference in healthcare decision making?","volume":"11","author":"Muhlbacher","year":"2013","journal-title":"Appl Health Econ Health Policy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40258-016-0299-1","article-title":"Amplifying each patient's voice: a systematic review of multi-criteria decision analyses involving patients","volume":"15","author":"Marsh","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.drudis.2018.09.015","article-title":"Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review","volume":"24","author":"van Overbeeke","year":"2019","journal-title":"Drug Discov Today"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1007\/s00464-014-4044-2","article-title":"Incorporating patient-preference evidence into regulatory decision making","volume":"29","author":"Ho","year":"2015","journal-title":"Surg Endoscopy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2016.04.008","article-title":"Patient preferences in regulatory benefit-risk assessments: a US perspective","volume":"19","author":"Johnson","year":"2016","journal-title":"Value Health"},{"key":"B6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40271-018-0344-2","article-title":"Patient perspectives on the value of patient preference information in regulatory decision making: a qualitative study in swedish patients with rheumatoid arthritis","volume":"12","author":"Bywall","year":"2019","journal-title":"Patient"},{"key":"B7","doi-asserted-by":"publisher","first-page":"22761","DOI":"10.3402\/jmahp.v2.22761","article-title":"The value of quantitative patient preferences in regulatory benefit-risk assessment","volume":"2","author":"Egbrink","year":"2014","journal-title":"J Mark Access Health Policy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1017\/S0266462311000523","article-title":"Integrating patients' views into health technology assessment: Analytic hierarchy process. (AHP) as a method to elicit patient preferences","volume":"27","author":"Danner","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1017\/S0266462314000282","article-title":"Patient perspective in health technology assessment of pharmaceuticals in Finland","volume":"30","author":"Kleme","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fmed.2018.00285","article-title":"Patient involvement in the lifecycle of medicines according to belgian stakeholders: the gap between theory and practice","volume":"5","author":"Janssens","year":"2018","journal-title":"Front Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.2147\/PPA.S176067","article-title":"Patients' preferences in periodontal disease treatment elicited alongside an IQWiG benefit assessment: a feasibility study","volume":"12","author":"Vennedey","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"B12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40271-017-0222-3","article-title":"Giving patients' preferences a voice in medical treatment life cycle: the PREFER public-private project","volume":"10","author":"de Bekker-Grob","year":"2017","journal-title":"Patient"},{"key":"B13","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1016\/j.jval.2014.08.1596","article-title":"A systematic review to identify the use of preference elicitation methods in health care decision making","volume":"17","author":"Janus","year":"2014","journal-title":"Value Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-016-0444-9","article-title":"Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers","volume":"11","author":"Morel","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12913-014-0540-2","article-title":"The use of research evidence on patient preferences in pharmaceutical coverage decisions and clinical practice guideline development: exploratory study into current state of play and potential barriers","volume":"14","author":"Utens","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.2147\/PPA.S122319","article-title":"Importance of hemodialysis-related outcomes: comparison of ratings by a self-help group, clinicians, and health technology assessment authors with those by a large reference group of patients","volume":"10","author":"Janssen","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"B17","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3389\/fphar.2017.00698","article-title":"Overview on patient centricity in cancer care","volume":"8","author":"Narbutas","year":"2017","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: a model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"J Gen Intern Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1177\/0272989X9901900104","article-title":"Measuring patient preferences by willingness to pay to avoid: the case of acute otitis media","volume":"19","author":"Sorum","year":"1999","journal-title":"Med Decis Making"},{"key":"B20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","article-title":"Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment","volume":"18","author":"Fifer","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/cpt.1231","article-title":"Patient-focused drug development methods for benefit-risk assessments: a case study using a discrete choice experiment for antiepileptic drugs","volume":"105","author":"Holmes","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1634\/theoncologist.2017-0257","article-title":"Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple Myeloma","volume":"23","author":"Postmus","year":"2018","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.dld.2017.06.015","article-title":"Therapy experiences and preferences among patients with anemia: Results of a cross-sectional survey among Italian patients with inflammatory bowel disease","volume":"49","author":"Milovanovic","year":"2017","journal-title":"Dig Liver Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jval.2016.11.023","article-title":"Be Careful What you ask for: effects of benefit descriptions on diabetes patients' benefit-risk tradeoff preferences","volume":"20","author":"von Arx","year":"2017","journal-title":"Value Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","article-title":"Patients' preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment","volume":"39","author":"Eliasson","year":"2017","journal-title":"Clin Ther"},{"key":"B26","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2147\/PPA.S121838","article-title":"Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments","volume":"11","author":"Eliasson","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"B27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jval.2016.12.015","article-title":"The probabilistic efficiency frontier: a framework for cost-effectiveness analysis in germany put into practice for hepatitis C treatment options","volume":"20","author":"Muhlbacher","year":"2017","journal-title":"Value Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jval.2016.02.014","article-title":"Developing a patient-centered benefit-risk survey: a community-engaged process","volume":"19","author":"Hollin","year":"2016","journal-title":"Value Health"},{"key":"B29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/mus.25411","article-title":"Patient-centered benefit-risk assessment in duchenne muscular dystrophy","volume":"55","author":"Hollin","year":"2017","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1080\/09546634.2016.1177161","article-title":"Benefit-risk tradeoff preferences for chronic hand eczema treatments","volume":"28","author":"Hauber","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"B31","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40271-016-0170-3","article-title":"A framework for instrument development of a choice experiment: an application to type 2 diabetes","volume":"9","author":"Janssen","year":"2016","journal-title":"Patient"},{"key":"B32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-016-0763-8","article-title":"Preferences for antiviral therapy of chronic hepatitis C: a discrete choice experiment","volume":"18","author":"Muhlbacher","year":"2017","journal-title":"Eur J Health Econ"},{"key":"B33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/cpt.332","article-title":"Incorporating patient preferences into drug development and regulatory decision making: results from a quantitative pilot study with cancer patients, carers, and regulators","volume":"99","author":"Postmus","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"B34","first-page":"42","article-title":"A discrete choice experiment to elicit patient willingness to pay for attributes of treatment-induced symptom relief in Comorbid. Insomnia","volume":"24","author":"Roy","year":"2015","journal-title":"Managed Care."},{"key":"B35","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.jval.2016.02.019","article-title":"A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies","volume":"19","author":"Ho","year":"2016","journal-title":"Value Health"},{"key":"B36","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/bcp.12566","article-title":"Understanding drug preferences, different perspectives","volume":"79","author":"Mol","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","article-title":"A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy","volume":"36","author":"Peay","year":"2014","journal-title":"Clin Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1524-4733.2010.00694.x","article-title":"Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes","volume":"13","author":"Johnson","year":"2010","journal-title":"Value Health"},{"key":"B39","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1524-4733.2004.74007.x","article-title":"Patient preference and willingness-to-pay (40) doifor Humalog Mix25 relative to Humulin 30\/70: a multicountry application of a discrete choice experiment","volume":"7","author":"Aristides","year":"2004","journal-title":"Value Health"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1002\/pds.4255","article-title":"MCDA swing weighting and discrete choice experiments for elicitation of patient benefit-risk preferences: a critical assessment","volume":"26","author":"Tervonen","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B41","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/14737167.2016.1115722","article-title":"Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy","volume":"16","author":"Mott","year":"2016","journal-title":"Exp Rev Pharmacoecon Outcomes Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jval.2016.04.006","article-title":"Patient-focused benefit-risk analysis to inform regulatory decisions: the European Union perspective","volume":"19","author":"Muhlbacher","year":"2016","journal-title":"Value Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40273-013-0118-6","article-title":"Why should regulators consider using patient preferences in benefit-risk assessment?","volume":"32","author":"van Til","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"B44","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s40273-017-0518-0","article-title":"Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet?","volume":"35","author":"Vass","year":"2017","journal-title":"Pharmacoeconomics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1017\/S0266462317000885","article-title":"Taking patient heterogeneity and preferences into account in health technology assessments","volume":"33","author":"Kievit","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"B46","year":"2016","journal-title":"Patient Preference Information\u2013Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling: Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/annonc\/mdr559","article-title":"Preferences for cancer treatments: an overview of methods and applications in oncology","volume":"23","author":"Blinman","year":"2012","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/cpt.198","article-title":"Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?","volume":"98","author":"Lipska","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","article-title":"Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force","volume":"14","author":"Bridges","year":"2011","journal-title":"Value Health"},{"key":"B50","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14737167.2017.1389648","article-title":"Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?","volume":"17","author":"Janssen","year":"2017","journal-title":"Exp Rev Pharmacoecon Outcomes Res"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.543046\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T04:40:42Z","timestamp":1603687242000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.543046\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":50,"alternative-id":["10.3389\/fmed.2020.543046"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.543046","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]},"article-number":"543046"}}